Revlimid lenalidomide: Phase II data

A Phase II trial in 69 previously untreated CLL patients showed that Revlimid plus rituximab led to an overall response rate (ORR) of 95% in patients <65 years of age (n=40), with 20% achieving a complete response (CR). At a median follow-up of 18 months, median PFS was 19 months. In 29 patients >=65 years of age, Revlimid plus rituximab led to a 78% ORR, with 7% achieving a CR. At a median follow-up of 17 months, median PFS was 20 months.

The most common grade 3/4 hematological adverse events reported in patients <65 years and >=65 years were neutropenia (53% and 62%, respectively), anemia (10% and 7%) and thrombocytopenia (3% and 3%). Data were presented at the American Society of Hematology meeting in San Diego. ...